Literature DB >> 32179482

Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple Sclerosis.

Jorge Maurino1, María L Martínez-Ginés2, José M García-Domínguez2, María D Solar3, María Carcelén-Gadea4, Adrián Ares-Luque5, Jordi Ballabriga6, Laura Navarro-Cantó7, Nicolás Medrano8, Cynthia A Honan9.   

Abstract

INTRODUCTION: In Multiple Sclerosis (MS), withdrawal from employment is a critical problem. This study explores relationships between disease characteristics, work difficulties, health-related quality of life, depression, and stigma and how these factors affect employment status.
METHODS: A multicenter, non-interventional, cross-sectional study was conducted in adults with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). Patient-reported questionnaires included: 23-item Multiple Sclerosis Work Difficulties Questionnaire, 29-item Multiple Sclerosis Impact Scale, Stigma Scale for Chronic Illness, and Beck Depression Inventory-Fast Screen.
RESULTS: A total of 199 individuals (mean age = 43.9 ± 10.5 years, 60.8% female, 86.4% with RRMS) participated in the study. Mean time from diagnosis was 9.6 ± 7.2 years and median Expanded Disability Status Scale score was 2.0 (interquartile range: 1.0-3.5). Employment rate was 47.2% (n = 94). Mean physical and psychological MSIS-29 impact sub-scores were 40.38 ± 17.1 and 20.24 ± 7.8, respectively. Forty patients (19.9%) had at least one SSCI-8 item with a score of 4 or 5, suggesting the presence of stigma often or always. Eighty-one patients (40.7%) were depressed and 25 (12.6%) had moderate-to-severe depression. Work difficulties were higher in those with worse functional status, a diagnosis of PPMS, and lower educational levels. Employed participants had lower perceptions of stigma and depressive symptoms than those not employed. Higher perceptions of stigma were also strongly linked to higher physical and psychological impact on health-related quality of life and greater work difficulties. Depressive symptoms were also strongly related to work-related problems.
CONCLUSIONS: Work difficulties, stigma and poor quality of life are common in MS patients, even in a population with low physical disability. Evaluation of these dimensions in clinical practice would allow the development of targeted rehabilitation and specific work plans for MS employers.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression; Employment; Health-related quality of life; Multiple sclerosis; Patient-reported outcomes; Stigma; Work difficulties

Year:  2020        PMID: 32179482     DOI: 10.1016/j.msard.2020.102046

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  9 in total

1.  Psychological Resilience as the Mediating Factor Between Stigma and Social Avoidance and Distress of Infertility Patients in China: A Structural Equation Modeling Analysis.

Authors:  Qing Zhao; Chaoji Huangfu; Junzheng Li; Huihui Liu; Nan Tang
Journal:  Psychol Res Behav Manag       Date:  2022-02-22

2.  The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life.

Authors:  Helen Beckmann; Christoph Heesen; Matthias Augustin; Christine Blome
Journal:  Int J MS Care       Date:  2021-12-07

3.  Occupational outcomes of people with multiple sclerosis: a scoping review.

Authors:  Bruno Kusznir Vitturi; Alborz Rahmani; Guglielmo Dini; Alfredo Montecucco; Nicoletta Debarbieri; Elvira Sbragia; Paolo Bandiera; Michela Ponzio; Mario Alberto Battaglia; Tommaso Manacorda; Benedetta Persechino; Giuliana Buresti; Matilde Inglese; Paolo Durando
Journal:  BMJ Open       Date:  2022-07-01       Impact factor: 3.006

Review 4.  Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.

Authors:  Arielle Kasindi; Dieu-Trang Fuchs; Yosef Koronyo; Altan Rentsendorj; Keith L Black; Maya Koronyo-Hamaoui
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

Review 5.  Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.

Authors:  Lynsey Lakin; Bryan E Davis; Cherie C Binns; Keisha M Currie; Mary R Rensel
Journal:  Neurol Ther       Date:  2021-04-20

6.  Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder.

Authors:  Jose E Meca-Lallana; Daniel Prefasi; Francisco Pérez-Miralles; Lucía Forero; María Sepúlveda; Carmen Calles; María L Martínez-Ginés; Inés González-Suárez; Sabas Boyero; Lucía Romero-Pinel; Ángel P Sempere; Virginia Meca-Lallana; Luis Querol; Lucienne Costa-Frossard; Hugo de Castro-Trapiello; Neus Canal; Jorge Maurino
Journal:  Patient Prefer Adherence       Date:  2021-04-12       Impact factor: 2.711

7.  Spatial and temporal distribution of the prevalence of unemployment and early retirement in people with multiple sclerosis: A systematic review with meta-analysis.

Authors:  Bruno Kusznir Vitturi; Alborz Rahmani; Guglielmo Dini; Alfredo Montecucco; Nicoletta Debarbieri; Paolo Bandiera; Mario Alberto Battaglia; Tommaso Manacorda; Benedetta Persechino; Giuliana Buresti; Michela Ponzio; Matilde Inglese; Paolo Durando
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

8.  Preferences Toward Attributes of Disease-Modifying Therapies: The Role of Nurses in Multiple Sclerosis Care.

Authors:  Beatriz Del Río-Muñoz; Cristina Azanza-Munarriz; Noelia Becerril-Ríos; Haydee Goicochea-Briceño; Rosalía Horno; Alejandro Lendínez-Mesa; César Sánchez-Franco; Mònica Sarmiento; Guillermo Bueno-Gil; Nicolás Medrano; Jorge Maurino
Journal:  J Neurosci Nurs       Date:  2022-06-13       Impact factor: 1.627

Review 9.  Stigma, Discrimination and Disclosure of the Diagnosis of Multiple Sclerosis in the Workplace: A Systematic Review.

Authors:  Bruno Kusznir Vitturi; Alborz Rahmani; Guglielmo Dini; Alfredo Montecucco; Nicoletta Debarbieri; Paolo Bandiera; Michela Ponzio; Mario Alberto Battaglia; Benedetta Persechino; Matilde Inglese; Paolo Durando
Journal:  Int J Environ Res Public Health       Date:  2022-08-02       Impact factor: 4.614

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.